Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -0.41
- Piotroski Score 2.00
- Grade Equal-weight
- Symbol (TRIB)
- Company Trinity Biotech plc
- Price $1.30
- Changes Percentage (-3.75%)
- Change -$0.05
- Day Low $1.24
- Day High $1.44
- Year High $3.55
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
- Last Earnings 05/27/2015
- Ex-Dividend for 5/16 Dividend 06/05/2015
- Dividend Payable 07/01/2015
- Today N/A
- Next Earnings (Estimated) 01/29/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $4.25
- Trailing P/E Ratio 0.49
- Forward P/E Ratio 0.49
- P/E Growth 0.49
- Net Income $-24,018,000
Income Statement
Quarterly
Annual
Latest News of TRIB
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Bangladesh tribunal will hear updates from police on their moves to arrest ousted premier Hasina
A special tribunal in Bangladesh will receive updates from police on the efforts to arrest former PM Sheikh Hasina and her aides for their alleged involvement in a mass uprising. Hasina fled to India ...
By AP NEWS | 23 hours ago -
Tim Weah back with the US after red card contributed to Copa America elimination, coaching change
Tim Weah returns to the US national team after a suspension for a red card incident at Copa America. Coach Pochettino praises his talent and character. Weah's performance is crucial for the team in up...
By AP NEWS | 1 day ago -
Trinity Biotech PLC (TRIB) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ...
The company expects $10 million in TrinScreen sales for the year, with around $3 million in revenue projected for Q4. Cost reduction initiatives aim to improve profitability by early 2025....
By Yahoo! Finance | 2 days ago
